Investigation of the Odilorhabdin Biosynthetic Gene Cluster Using NRPS Engineering
Angewandte Chemie International Edition · 12.08.2024 · 63 (33)
DOI: 10.1002/anie.202406389 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 10.07.2024. Verfasst von Leonard Präve und 5 weiteren Autor:innen. Beteiligte Einrichtung: Max-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions, 35043, Marburg, Germany. Hauptthemen laut MEDLINE: Peptide Synthases, Multigene Family, Xenorhabdus. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HORIZON EUROPE European Research Council, Innovative Medicines Initiative.
Abstract (Originalsprache)
The recently identified natural product NOSO‐95A from entomopathogenic Xenorhabdus bacteria, derived from a biosynthetic gene cluster (BGC) encoding a non‐ribosomal peptide synthetase (NRPS), was the first member of the odilorhabdin class of antibiotics. This class exhibits broad‐spectrum antibiotic activity and inspired the development of the synthetic derivative NOSO‐502, which holds potential as a new clinical drug by breaking antibiotic resistance. While the mode of action of odilorhabdins was broadly investigated, their biosynthesis pathway remained poorly understood. Here we describe the heterologous production of NOSO‐95A in Escherichia coli after refactoring the complete BGC. Since the production titer was low, NRPS engineering was applied to uncover the underlying biosynthetic principles. For this, modules of the odilorhabdin NRPS fused to other synthetases were co‐expressed with candidate hydroxylases encoded in the BGC allowing the characterization of the biosynthesis of three unusual amino acids and leading to the identification of a prodrug‐activation mechanism by deacylation. Our work demonstrates the application of NRPS engineering as a blueprint to mechanistically elucidate large or toxic NRPS and provides the basis to generate novel odilorhabdin analogues with improved properties in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Max-Planck-Institute for Terrestrial Microbiology, Department of Natural Products in Organismic Interactions, 35043, Marburg, Germany.
- Molecular Biotechnology, Department of Biosciences, Goethe-University Frankfurt, 60438, Frankfurt, Germany.
- Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, Department of Pharmacy, Saarbrücken, Germany.
- German Centre for Infection Research (DZIF), Hannover-Braunschweig, Germany.
- Myria Biosciences AG, Hochbergerstrasse 60 C, 4057, Basel, Switzerland.
- Present address: Synthetic Biology of Microbial Natural Products (SIMS), Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University Campus, 66123, Saarb…
ORCID-Profile: Helge B Bode
Förderung
- HORIZON EUROPE European Research Council
- Innovative Medicines Initiative
Zitieren
APA
Präve, L., Seyfert, C. E., Bozhüyük, K. A. J., Racine, E., Müller, R., & Bode, H. B. (2024). Investigation of the Odilorhabdin Biosynthetic Gene Cluster Using NRPS Engineering. Angewandte Chemie International Edition, 63(33). https://doi.org/10.1002/anie.202406389
Vancouver
Präve L, Seyfert CE, Bozhüyük KAJ, Racine E, Müller R, Bode HB. Investigation of the Odilorhabdin Biosynthetic Gene Cluster Using NRPS Engineering. Angewandte Chemie International Edition. 2024;63(33). doi:10.1002/anie.202406389
BibTeX
@article{Prve2024,
author = {Präve, Leonard and Seyfert, Carsten E and Bozhüyük, Kenan A J and Racine, Emilie and Müller, Rolf and Bode, Helge B},
title = {Investigation of the Odilorhabdin Biosynthetic Gene Cluster Using NRPS Engineering},
journal = {Angewandte Chemie International Edition},
year = {2024},
volume = {63},
number = {33},
doi = {10.1002/anie.202406389}
}
EUVIMED